AR059688A1 - Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus - Google Patents

Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus

Info

Publication number
AR059688A1
AR059688A1 ARP070100833A ARP070100833A AR059688A1 AR 059688 A1 AR059688 A1 AR 059688A1 AR P070100833 A ARP070100833 A AR P070100833A AR P070100833 A ARP070100833 A AR P070100833A AR 059688 A1 AR059688 A1 AR 059688A1
Authority
AR
Argentina
Prior art keywords
antigen
toxin
alpha
aureus
staphylococcus
Prior art date
Application number
ARP070100833A
Other languages
English (en)
Inventor
Kimberly L Taylor
All I Fattom
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of AR059688A1 publication Critical patent/AR059688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Vacunas que comprenden un antígeno de alfa-toxina de S. aureus y un vehículo aceptable para el uso farmacéutico, y que son utiles para tratar y prevenir infecciones. El antígeno de alfa-toxina de S. aureus puede contener al menos dos alteraciones que reducen su toxicidad, y/o puede estar conjugado o puede co-administrarse con otro antígeno bacteriano. Las vacunas pueden comprender uno o más antígenos bacterianos adicionales. También se proporcionan composiciones de anticuerpos que comprenden anticuerpos contra la alfa-toxina, y opcionalmente uno o más antígenos bacterianos adicionales, y que son utiles para tratar y prevenir infecciones. Reivindicacion 1: Una composicion de antígenos estafilococica pentavalente que comprende (i) un antígeno de Tipo 5 de S. aureus, (ii) un antígeno de Tipo 8 de S. aureus, (iii) un antígeno 336 de S. aureus, (iv) un antígeno de alfa-toxina de S. aureus y (y) un antígeno de leucocidina estafilococica.
ARP070100833A 2006-06-12 2007-02-28 Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus AR059688A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81259806P 2006-06-12 2006-06-12
US87536306P 2006-12-18 2006-12-18

Publications (1)

Publication Number Publication Date
AR059688A1 true AR059688A1 (es) 2008-04-23

Family

ID=38278910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100833A AR059688A1 (es) 2006-06-12 2007-02-28 Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus

Country Status (12)

Country Link
US (2) US20080131457A1 (es)
EP (2) EP2719397A1 (es)
JP (2) JP2009539979A (es)
KR (1) KR20090019007A (es)
CN (2) CN101466406B (es)
AR (1) AR059688A1 (es)
AU (1) AU2007259415B2 (es)
CA (1) CA2655133C (es)
MX (1) MX2008015814A (es)
NZ (2) NZ597046A (es)
TW (1) TW200744632A (es)
WO (1) WO2007145689A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
CN102698261A (zh) * 2005-06-13 2012-10-03 葛兰素史密斯克蓝生物品公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
CN101466406B (zh) * 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
RU2677140C1 (ru) * 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
SG10201600899PA (en) * 2011-02-08 2016-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
JP2014507142A (ja) 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
LT3403669T (lt) 2011-06-19 2020-10-12 New York University Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai
BR112013032911A2 (pt) 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida
IN2014CN02152A (es) 2011-09-01 2015-09-04 Novartis Ag
JP2015500864A (ja) 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
EP2668208B1 (en) 2012-04-17 2015-06-03 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody
CN112316135A (zh) 2012-11-06 2021-02-05 米迪缪尼有限公司 治疗金黄色葡萄球菌相关疾病的方法
AU2013341361A1 (en) 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
WO2014187746A2 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
JP6473746B2 (ja) * 2013-10-17 2019-02-20 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
WO2017026301A1 (ja) * 2015-08-10 2017-02-16 株式会社微生物化学研究所 黄色ブドウ球菌不活化菌体とロイコシジンを混合したワクチン
CN108367062B (zh) 2015-10-13 2022-05-06 赛诺菲巴斯德有限公司 抗金黄色葡萄球菌的免疫原性组合物
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
CN105695357A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种筛选高产α毒素的金黄色葡萄球菌菌株方法
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
JP4087896B2 (ja) 1991-11-22 2008-05-21 ナビ・バイオフアーマシユテイカルズ スタフィロコッカス・エピダーミジス関連ｉ及びｉｉ型表面抗原
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
EP2305294B1 (en) * 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
DK1838341T3 (da) * 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
CN102698261A (zh) * 2005-06-13 2012-10-03 葛兰素史密斯克蓝生物品公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
CN101466406B (zh) * 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途

Also Published As

Publication number Publication date
EP2719397A1 (en) 2014-04-16
JP2009539979A (ja) 2009-11-19
EP2043690A1 (en) 2009-04-08
NZ597046A (en) 2014-01-31
NZ574057A (en) 2012-01-12
AU2007259415A1 (en) 2007-12-21
CN102743747A (zh) 2012-10-24
WO2007145689A1 (en) 2007-12-21
US20080131457A1 (en) 2008-06-05
CN101466406B (zh) 2012-06-27
JP2013151526A (ja) 2013-08-08
CN101466406A (zh) 2009-06-24
KR20090019007A (ko) 2009-02-24
AU2007259415B2 (en) 2013-09-26
CA2655133A1 (en) 2007-12-21
MX2008015814A (es) 2009-01-12
US20090053235A1 (en) 2009-02-26
TW200744632A (en) 2007-12-16
CA2655133C (en) 2018-03-20

Similar Documents

Publication Publication Date Title
AR059688A1 (es) Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
DOP2006000268A (es) Agentes antibacterianos
PE20142188A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
NZ595689A (en) Compositions for immunising against staphylococcus aureus
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
AR089004A1 (es) Composiciones farmaceuticas inyectables, metodo, uso
UY28769A1 (es) Métodos para controlar agentes patógenos en plantas usando n-fosfonometilglicina
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
CL2008001983A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras.
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
CY1112160T1 (el) Χρησιμα αντιβιοτικα μονοβακταμης
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
CO2019011264A2 (es) Nanosistemas que comprenden plata y antibióticos y su uso para el tratamiento de infecciones bacterianas
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis
CY1117501T1 (el) Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal